Goldman Sachs sets new Biogen stock price target on bold Alzheimer's bet
Biogen (NASDAQ: BIIB) has had a rocky few years. Its multiple sclerosis franchise has been bleeding[……] Read More
Biogen (NASDAQ: BIIB) has had a rocky few years. Its multiple sclerosis franchise has been bleeding[……] Read More